Role for NF-κB in mediating the effects of hyperoxia on IGF-binding protein 2 promoter activity in lung alveolar epithelial cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1448, Issue 3, 1999, Pages 349-362

  Cazals, Véronique ^a   Nabeyrat, Elodie ^a   Corroyer, Sophie ^a   De Keyzer, Yves ^b   Clement, Annick ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA TRANSFECTION; ELECTROPHORETIC MOBILITY; EXTRACT; HYPEROXIA; IMMUNOBLOTTING; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; NEWBORN; NONHUMAN; OXIDATIVE STRESS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELL CYCLE; CELL DIVISION; CELL LINE; DNA; DNA PROBES; EPITHELIAL CELLS; HYPEROXIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PULMONARY ALVEOLI; RATS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 0032910693     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(98)00095-0     Document Type: Article

References (53)

1. Quinlan T., Marsh J., Janssen Y., Borm P., Mossman B. Oxygen radicals and asbestos-mediated disease. Environ. Health Perspect. 10:1994;107-110.
2. Urban T., Hurbain I., Urban M., Clement A., Housset B. Oxidants and antioxidants. Biological effects and therapeutic perspectives. Ann. Chir. 49:1995;427-434.
3. Bender K., Blattner C., Knebel A., Iordanov M., Herrlich P., Rahmsdorf H. UV-induced signal transduction. J. Photochem. Photobiol. 37:1997;1-17.
4. Crapo J., Barry B., Gehr P., Bachofen M., Weibel E. Cell number and cell characteristics of the normal human lung. Am. Rev. Respir. Dis. 125:1982;740-745.
5. Adamson I., Bowden D. Type 2 cell as progenitor of alveolar epithelial regeneration: cytodynamic study in mice after exposure to oxygen. Lab. Invest. 30:1974;15-23.
6. Adamson I., Bowden D. Derivation of type 1 epithelium from type 2 cell in the developing rat lung. Lab. Invest. 32:1975;736-745.
7. Castranova V., Rabovsky J., Tucker J., Miles P. The alveolar type II epithelial cell: a multifunctional pneumocyte. Toxicol. Appl. Pharmacol. 93:1988;472-483.
8. Witschi H. Responses of the lung to toxic injury. Environ. Health Perspect. 85:1990;5-13.
9. Miller B., Hook G. Hypertrophy and hyperplasia of alveolar type II cells in response to silica and other pulmonary toxicants. Environ. Health Perspect. 85:1990;15-23.
10. Clement A., Campisi J., Farmer S., Brody J. Constitutive expression of growth-related mRNAs in proliferating and nonproliferating lung epithelial cells in primary culture: evidence for growth-dependent translational control. Proc. Natl. Acad. Sci. USA. 87:1990;318-322.
11. Clement A., Edeas M., Chadelat K., Brody J. Inhibition of lung epithelial cell proliferation by hyperoxia. Posttranscriptional regulation of proliferation-related genes. J. Clin. Invest. 90:1992;1812-1818.
12. Corroyer S., Maitre B., Cazals V., Clement A. Altered regulation of G1 cyclins in oxidant-induced growth arrest of lung alveolar epithelial cells: accumulation of inactive cyclin E-CDK2 complexes. J. Biol. Chem. 271:1996;25117-25125.
13. Kaufmann W., Paules R. DNA damage and cell cycle checkpoints. FASEB J. 10:1996;238-247.
14. Cazals V., Mouhieddine B., Maitre B., Le Bouc Y., Chadelat K., Brody J., Clement A. Insulin-like growth factors: their binding proteins and transforming growth factor-beta 1 in oxidant-arrested lung alveolar epithelial cells. J. Biol. Chem. 269:1994;14111-14117.
15. Mouhieddine O., Cazals V., Maitre B., Le Bouc Y., Chadelat K., Clement A. Insulin-like growth factor-II (IGF-II) type 2 IGF receptor and IGF-binding protein-2 gene expression in rat lung alveolar epithelial cells: relation to proliferation. Endocrinology. 135:1994;83-91.
16. Mouhieddine O., Cazals V., Kuto E., Le Bouc Y., Clement A. Glucocorticoid-induced growth arrest of lung alveolar epithelial cells is associated with increased production of insulin-like growth factor binding protein-2. Endocrinology. 137:1996;287-295.
17. Baeuerle P., Baltimore D. NF-κB: ten years after. Cell. 87:1996;13-20.
18. Beg A., Ruben S., Scheinman R., Haskill S., Rosen C., Baldwin A. Jr. IkB interacts with the nuclear localization sequences of the subunits of NF-kB: a mechanism for cytoplasmic retention. Curr. Opin. Cell Biol. 6:1992;1899-1913.
19. Liou H., Baltimore D. Regulation of the NF-κB/rel transcription factor and IκB inhibitor system. Curr. Opin. Cell Biol. 5:1993;477-487.
20. Abraham E. NF-κB and reactive oxygen intermediates. Shock. 7:1997;441-453.
21. Sen C., Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10:1996;709-720.
22. Siebenlist U. NF-κB/IκB proteins. Their role in cell growth differentiation and development. Madrid, Spain, July 7-10 1996. Biochim. Biophys. Acta. 1332:1997;22-35.
23. Weil R., Laurent-Winter C., Israel A. Regulation of IkappaBbeta degradation. Similarities to and differences from IkappaBalpha. J. Biol. Chem. 272:1997;9942-9949.
24. Baeuerle P. The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim. Biophys. Acta. 1072:1991;63-80.
25. Clement A., Steele M., Brody J., Riedel N. SV40T-immortalized lung alveolar epithelial cells display post-transcriptional regulation of proliferation-related genes. Exp. Cell Res. 196:1991;198-205.
26. 3H thymidine incorporation does not correlate with growth state in cultured alveolar type II cells. Am. J. Respir. 3:1990;159-164.
27. Kutoh E., Margot J., Schwander J. Genomic structure and regulation of the promoter of the rat insulin-like growth factor binding protein-2 gene. Mol. Endocrinol. 7:1993;1205-1216.
28. Schreck R., Baeuerle P. Assessing oxygen radicals as mediators in activation of inducible eukaryotic transcription factor NF-κB. Methods Enzymol. 234:1994;151-163.
29. Bertrand F., Philippe C., Antoine P., Baud L., Groyer A., Capeau J., Cherqui G. Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway. J. Biol. Chem. 270:1995;24435-24441.
30. Zhang P., Mellon S. Multiple orphan nuclear receptors converge to regulate rat P450c17 gene transcription: novel mechanisms for orphan nuclear receptor action. Mol. Endocrinol. 11:1997;891-904.
31. Pessara U., Koch N. Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element. Mol. Cell. Biol. 10:1990;4146-4154.
32. Vaulont S., Puzenat N., Levrat F., Cognet M., Kahn A., Raymondjean M. Proteins binding to the liver-specific pyruvate kinase gene promoter. A unique combination of known factors. J. Mol. Biol. 209:1989;205-219.
33. Vaulont S., Puzenat N., Kahn A., Raymondjean M. Analysis by cell-free transcription of the liver-specific pyruvate kinase gene promoter. Mol. Cell. Biol. 9:1989;4409-4415.
34. Bessho, R., Matsubara, K., Kubota, M., Kuwadado, K., Hirota, H., Wakazono, Y., Lin, Y., Okuda, A., Kawai, M., Nishikomori, R. et al., Pyrrolidine dithiocarbamate a potent inhibitor of nuclear factor kappa B (NF-κB) activation prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes, Biochem. Pharmacol. 48 (1993) 1883-1889.
35. Schreck R., Meier B., Mannel D., Droge W., Baeuerle P. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175:1992;1181-1194.
36. Shambaugh G., Lee R., Watanabe G., Erfurth F., Karnezis A., Koch A., Haines G., Halloran M., Brody B., Pestell R. Reduced cyclin D1 expression in the cerebella of nutritionally deprived rats correlates with developmental delay and decreased cellular DNA synthesis. J. Neuropathol. Exp. Neurol. 55:1996;1009-1020.
37. Brennan P., O'Neill L. Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals. Biochim. Biophys. Acta. 1260:1995;167-175.
38. Freeman B., Topolosky M., Crapo J. Hyperoxia increases oxygen radical production in rat lung homogenates. Arch. Biochem. Biophys. 216:1982;477-484.
39. Meister A. Selective modification of glutathione metabolism. Science. 220:1983;472-477.
40. Meister A., Anderson M. Glutathione. Annu. Rev. Biochem. 52:1983;711-760.
41. Messina J., Lawrence D. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase. J. Immunol. 143:1989;1974-1981.
42. Franzoso G., Carlson L., Brown K., Daucher M., Bressler P., Siebenlist U. Activation of the serum response factor by p65/NF-κB. EMBO J. 15:1996;3403-3412.
43. DiDonato J., Mercurio F., Rosette C., Wu-Li J., Suyang H., Ghosh S., Karin M. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16:1996;1295-1304.
44. Chen Z., Parent L., Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 84:1996;853-862.
45. Doree M., Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J. 8:1994;1114-1121.
46. Resnitzky D., Reed S. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol. Cell. Biol. 15:1995;3463-3469.
47. Sherr C., Roberts J. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
48. Yang Z., Perkins N., Ohno T., Nabel E., Nabel G. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med. 1:1995;1052-1056.
49. Perkins N., Felzien L., Betts J., Leung K., Beach D., Nabel G. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science. 275:1997;523-527.
50. Park J., McCusker R., Vanderhoof J., Mohammadpour H., Harty R., MacDonald R. Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: implications for autocrine growth regulation. Growth Regul. 131:1992;1359-1368.
51. Rechler M. Growth inhibition by insulin-like growth factor (IGF) binding protein-3 - What's IGF got to do with it? Endocrinology. 138:1997;2645-2650.
52. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
53. Wu H., Lozano G. NF-κB activation of p53. J. Biol. Chem. 269:1994;20067-20074.